key: cord-0850635-zg46xikf authors: García-Azorín, David; Abildúa, María José Abenza; Aguirre, María Elena Erro; Fernández, Santiago Fernández; Moncó, Juan Carlos García; Guijarro, Cristina; Platas, Montserrat González; Delgado, Fernando Romero; Andrés, José Miguel Láinez; Ezpeleta, David title: Neurological presentations of COVID-19: Findings from the Spanish society of neurology neuroCOVID-19 registry date: 2020-12-19 journal: J Neurol Sci DOI: 10.1016/j.jns.2020.117283 sha: 28e9a27cefa28f7fbfffc51140b755aa55509072 doc_id: 850635 cord_uid: zg46xikf OBJECTIVE: We report the findings from the Spanish Society of Neurology's NeuroCOVID-19 Registry. METHODS: We performed a multicentre study of patients with neurological manifestations of COVID-19. Participating physicians reported demographic, clinical, and paraclinical data and judged the involvement of COVID-19 in causing neurological symptoms. RESULTS: A total of 233 cases were submitted, including 74 different combinations of manifestations. The most frequently reported were stroke (27%), neuromuscular symptoms (23.6%), altered mental status (23.6%), anosmia (17.6%), headache (12.9%), and seizures (11.6%). The mean age of patients was 61.1 years, with 42.1% being women; a higher proportion of women was recorded among patients with altered mental status, anosmia, and headache. The onset of symptoms differed within categories. Onset of anosmia occurred a mean (standard deviation) of 2.9 (2.5) days after the first general symptom, whereas neuromuscular symptoms appeared after 13.9 (10.1) days. Neurological symptoms were persistent in 33% of patients. General symptoms were present in 97.7% of patients, and results from general laboratory studies were abnormal in 99.4% of patients. Cerebrospinal fluid analysis findings were abnormal in 62.7% of the cases in which this test was performed (n = 51), but positive results for SARS-CoV-2 were only found in one case. CONCLUSIONS: The neurological manifestations of COVID-19 are diverse. Anosmia, myalgia, and headache occur earlier in the course of the disease. Altered mental status, neuromuscular symptoms, and stroke are associated with greater severity. COVID-19 must be incorporated into most clinical and radiological differential diagnoses. COVID-19 may cause persistent and disabling neurological symptoms. The coronavirus disease 2019 (COVID- 19) pandemic has challenged healthcare systems worldwide. Clinicians and neurologists have been obliged to familiarise themselves with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in record time. 1 Spain has been one of the most severely affected countries worldwide, having been struck since the very onset of the pandemic. 2 The Spanish Society of Neurology (SEN) created a task force to review the existing evidence about previous coronaviruses and the exponentially increasing evidence about COVID-19. 3 The first large series described a relatively low frequency of mostly non-specific neurological symptoms, including myalgia, headache, anosmia, and altered mental status. [4] [5] [6] [7] However, since the publication of the initial neurological series and cases, the number and frequency of neurological manifestations have significantly increased. 8, 9 The SEN created a nation-wide registry of COVID-19 cases with neurological manifestations. 10 The main objectives were to raise awareness about the different neurological presentations and to report weekly to SEN members about the collected data. The purpose of this study is to present the findings from the registry and to discuss the clinical implications for the management of neuroCOVID-19. We performed an observational, descriptive, multicentre study of a series of patients with COVID-19 presenting neurological manifestations during the course of the disease. Hospital admission was not a requisite for inclusion in the registry, and both inpatients and outpatients were included. All neurologists belonging to the SEN were informed The description of the clinical presentation included general symptoms (arthralgia, asthenia, weakness, diarrhoea, dyspnoea, chest pain, expectoration, fever, lightheadedness, odynophagia, skin rash, cough, vomiting, and others). We analysed whether patients also presented headache, anosmia, and/or myalgia, given that these symptoms were commonly reported in clinical series. The severity of COVID-19 disease was classified as mild disease, pneumonia, acute respiratory distress syndrome (ARDS) 11 (supplementary material), and other complications (cardiac insufficiency, acute kidney injury, septic shock, disseminated intravascular coagulation, and others). The need for intensive care unit (ICU) admission was also recorded. Participants indicated whether COVID-19 was diagnosed by polymerase chain reaction (PCR), serological testing, quick tests, or based on clinical signs and symptoms. 12 Due to a shortage of reagents during the peak of the pandemic, some local protocols allowed COVID-19 diagnosis based on the typical clinical picture, prior contact with a patient with COVID-19, and lack of a more plausible explanation for the patient's symptoms. Participants were instructed to report cases without diagnostic confirmation when these were not better accounted for by another diagnosis. Abnormal results from the general laboratory analysis were recorded, including leucocytosis, lymphocytosis, lymphopenia, anaemia, thrombocytopaenia, increased liver enzymes, increased lactate dehydrogenase (LDH), rhabdomyolysis, decreased glomerular filtration rate, and abnormal coagulation parameters. The results of specific neurological work-up were specifically assessed. We analysed whether cerebrospinal fluid (CSF) was tested and recorded the presence of pleocytosis, increased protein levels, hypoglycorrhachia, and increased CSF opening pressure. Participants reported whether CSF samples were tested for SARS-CoV-2 with PCR. The study protocol was approved by the Ethics Review Board of Hospital Clínico Figure 1 shows the number of patients that were eligible for each analysis. Patients' mean (SD) age was 61. Endocrine disorders (n, %) 21 (9.7%) 217 Nephro-urological disorders (n, %) 13 (6.0%) 217 Psychiatric disorders (n, %) 12 (5.5%) 217 Cancer (n, %) 11 (5.1%) 217 Gastrointestinal disorders (n, %) 5 (2.3%) 217 Haematological diseases (n, %) 4 (1.8%) 217 Immunosuppression (n, %) 2 (0.9%) 217 Dermatological diseases (n, %) 2 (0.9%) 217 Rheumatoid arthritis (n, %) 2 (0.9%) 217 J o u r n a l P r e -p r o o f Chronic infections (n, %) Genetic disorders (n, %) 2 (0.9%) 217 Pregnancy (n, %) 1 (0.4%) 217 SD: standard deviation. Information about the general symptoms of COVID-19 was available in 220 (94.4%) cases. The most frequent general symptoms were fever and cough. Five (2.3%) patients had no general symptoms and for two (0.9%) patients this information was not available due to the lack of relatives and hyperacute presentation of the neurological symptoms (basilar artery stroke and left middle cerebral artery stroke). Table 2 summarises the type and frequency of general symptoms, headache, anosmia, and myalgia. When comparing the six most frequently represented categories of manifestations, statistically significant differences were observed in age; frequency of general comorbidities; frequency of fever, headache, and anosmia; and time between onset of general COVID-19 symptoms and onset of neurological symptoms (Table 3 ). Figure 2 shows the one-minus-survival curve of time to the onset of neurological symptoms within those groups. The percentage of patients with sequelae is calculated according to the total of patients per category minus those who died. SD: standard deviation. Since the beginning of the COVID-19 pandemic, neurologists worldwide have been eager to understand the neurotropism of SARS-CoV-2. 10, 13 In this study, we present the results of the national registry of the Spanish Society of Neurology. The main finding of the study is that COVID-19 has a wide range of neurological manifestations, which may coexist and occur early in the course of the disease, and occasionally persist. Until the discovery of an effective treatment or the anticipated vaccine, clinicians must be alert to the neurological symptoms of COVID-19. Neurological symptoms are the most frequent extra-pulmonary symptoms of the virus. They are described in 36.4%-57.4% of hospitalised patients [5] [6] [7] [8] [9] and 84% of patients admitted to intensive care units. 14 Neurological symptoms have been classified J o u r n a l P r e -p r o o f according to the anatomical location of the lesion, into symptoms originating in the central nervous system, symptoms originating in the peripheral nervous system, and muscular manifestations. 5 Other authors classify them as non-specific and specific symptoms. 15 In our opinion, the term "non-specific" can be confusing, as no pathognomonic sign or symptom of neuroCOVID-19 has yet been identified. We could classify neurological symptoms into non-focal, generalised symptoms, such as myalgia, headache, anosmia, light-headedness, and altered mental status; and focal symptoms, including stroke, seizures, radiculopathies, cranial nerve syndromes, encephalitis, and movement disorders. 8, 9 The present study may not reflect the true epidemiology and frequency of the different neurological symptoms, as other international registries have done 3,10,16 ; however, it enables comparison of some other relevant data, such as the time between onset of the disease and onset of neurological symptoms. Indeed, one of our most relevant findings is that non-focal generalised symptoms tend to occur earlier, and frequently co-present, while other symptoms, such as stroke or seizures, may appear later in the course of the disease. 16, 17 This is probably associated with the pathophysiology of neuroCOVID-19. The cause of the neurological symptoms may be related with the host's immune response against the virus, 18 as is probably the case with such symptoms as headache 18 or myalgia, which are probably associated with the release of cytokines and inflammatory agents. [19] [20] [21] [22] Indeed, some studies report better in-hospital prognosis in patients with headache 18 or anosmia, 23 when compared with other patients. The fact that angiotensin-converting enzyme 2 receptor, targeted by the SARS-CoV-2 spike protein, 24 is highly expressed in the upper respiratory tract could also explain anosmia and some phenotypic features of headache, such as the frontal predominance and the frequency of cranial autonomic symptoms. 25 The systemic consequences of the infection, such as hypoxaemia, acute kidney injury, hepatic failure, and ionic imbalance, 26 as well as the drugs employed in treatment, may play a role in the pathogenesis of such symptoms as altered mental status and seizures in some cases. 8, 9, 27 Proper work-up of patients with neurological symptoms obliges us to consider and rule out COVID-19 in most cases. In cases with no known cause, complete neurological work-up must be performed, including cranial imaging, EEG, and CSF analysis. 10 These studies frequently return positive results in adequately selected J o u r n a l P r e -p r o o f patients. 13, 14 Patients with prolonged hospital stays, and particularly those admitted to the ICU, might present complications related to prolonged bed rest and/or superinfection. 27 The neurovirulence of SARS-CoV-2 has been widely discussed. Initially, reported cases of positive PCR results for SARS-CoV-2 in the CSF were exceptional. [5] [6] [7] [8] [9] [11] [12] [13] [14] 16, 28 The neuroinvasion of the virus remains controversial. [42] [43] [44] Several routes of entry have been proposed, including the olfactory nerve, the vascular endothelium, migration of leukocytes towards the blood-brain barrier, and trans-synaptic transfer through infected neurons. [42] [43] [44] The SARS-CoV-2 spike protein and ACE receptors have been suggested as the key mechanism in the infection of cells, and this receptor is also expressed in the blood-brain barrier. 44 26 We do not report information on neurological examination as it was freely described by participating physicians. Specific details about the clinical phenotype of some presentations, such as headache, seizures, or neuromuscular disorders were not reported, and should be described in specific series. Neuroimaging studies and CSF analyses were not conducted systematically, and these results should be interpreted with caution, given the high risk of reporting bias. In addition, the causality of the neurological symptoms was judged subjectively. A classification of the type of neurological manifestations, pathophysiology, and causal role of the virus is needed. The Table 1 : Demographic variables and frequency of comorbidities. The need for neurologists in the care of COVID-19 patients The first months of the COVID-19 pandemic in Spain. Health policy technol 2020 World Federation of Neurology Enviromental Neurology Specialty Group. COVID-19 international neurological registries Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details Central nervous system manifestations of COVID-19: A systematic review Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry Neurological manifestations in a prospective unselected series of hospitalized COVID-19 patients The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the Laboratory testing for 2019 novel coronavirus (2019)-nCoV) in suspected human cases Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic Neurologic features in severe SARS-CoV-2 infection Neurological complications of coronavirus and COVID-19 The international EAN survey on neurological symptoms in patients with COVID-19 infection Beyond fever, cough and dyspnea: The neurology of COVID-19 Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study COVID-19: Consider cytokine storm syndromes and immunosuppression The cytokine storm and COVID-19 The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammation events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients Anosmia is associated with lower in-hospital mortality in COVID-19 High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients Neurological comorbidity is a predictor of death in Covid-19 disease: A cohort study on 575 patients Altered mental status as a novel initial clinical presentation for COVID-19 infection in the elderly Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms COVID-19 encephalopathy: detection of antibodies against SARS-CoV-2 in CSF Headache and imaired conciousness level associated with SARS-CoV-2 in CSF: A case report Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology COVID-19-associated acute disseminated encephalomyelitis (ADEM) Acute disseminated encephalomyelitis after SARS-CoV-2 infection Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases Miller Fisher syndrome and polyneuritis cranialis in COVID-19 Acute stroke care is at risk in the era of COVID-19: experience at a comprehensive stroke center in Barcelona Impact of COVID-19 outbreak on ischemic stroke admissions and in-hospital mortality in North-West Spain Cerebrovascular disease in patients J o u r n a l P r e -p r o o f Journal Pre-proof with COVID-19: neuroimaging, histological and clinical description Neuropathological features of Covid-19 Neuroanatomical substrates of generalized brain dysfunction in COVID-19 Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review Neurological complications associated with the Blood-brain barrier damage induced by the inflammatory response during SARS-CoV-2 infection Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in COVID-19 patients Frequency and type of red flags in patients with Covid-19 and headache: a series of 104 hospitalized patients The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings Nervous system involvement in COVID-19: results from a retrospective consecutive neuroimaging cohort Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study Acknowledgements : We want to thank the information technology department and the secretarial staff of the SEN for their support during the pandemic. We thank Cristina de Leon Cárdenas, Napuca García Fernández and Jack Leyden for editing the manuscript.Funding:This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest to declare.